

I'm not done yet

Who Is a Candidate for CYRAMZA?



Clinical factors:

- Unresectable stage IV adenocarcinoma of the stomach or GEJ
- Progressed after Platinum- and/or Fluoropyrimidine-containing 1L
- ECOG PS 0-1
- Regardless of initially tested HER2 status



Symptoms:

- Difficulty swallowing
- Nausea and vomiting
- Weight loss






I'm not done yet



Metastatic Gastric Cancer and GEJ Adenocarcinoma Are Rapid Progressing and Symptomatic

Without Active 2nd-Line Treatment at Post-1st-Line Progression, OS Is <4 Months and PFS Is <1.5 Months¹

83C Arm of the REGARD Trial



1-year OS:

11.8%

Common symptoms of gastric cancer/GEJ adenocarcinoma patients:²

- Dysphagia
- Weight loss
- Epigastric pain
- Dyspepsia
- Reflux
- Nausea or vomiting
- Abdominal pain
- Chest pain
- Constipation

I'm not done yet

Metastatic Gastric Cancer and GEJ Adenocarcinoma Are Rapid Progressing and Symptomatic

Without Active 2nd-Line Treatment at Post-1st-Line Progression, OS Is <4 Months and PFS Is <1.5 Months¹



References:

1. Fuchs CS, et al. Ramucicromab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet* 2014;383(9911):31-39.
2. Stapley S, et al. The risk of oesophago-gastric cancer in symptomatic patients in primary care: a large case-control study using electronic records. *Br J Cancer* 2013;108:25-31.



- Chest pain
- Constipation